FDA approves GSK hepatitis B drug that can keep virus in check after treatment ends
In two late-stage trials, nearly 1 in 5 patients who took bepirovirsen kept the virus undetectable for at least 24 weeks off all therapy. No one on placebo did.
Health
Iris Walker
Iris Walker writes about health research, with a focus on the background needed to interpret new papers and public announcements. Her coverage connects findings with earlier evidence and explains the questions researchers are investigating. She emphasizes clear terminology, appropriate context, and the uncertainties that remain as scientific understanding develops.
Stories by Iris Walker